About Koninklijke Philips N.V. NY Registry Shares (PHG)
Koninklijke Philips Electronics is a global leader in health technology, focused on improving people's lives through meaningful innovation. The company develops a wide range of products and solutions, including medical devices, diagnostic imaging, patient monitoring systems, and consumer health products. Its commitment to enhancing healthcare and well-being extends into areas such as personal health, connected care, and sustainable development, aiming to deliver integrated solutions that empower both health professionals and patients. Philips combines advanced technologies with deep clinical and consumer insights to create solutions that drive better outcomes and improve the quality of care across various settings. Read More
In a move that has sent shockwaves through the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180.00 per share in an all-cash transaction. The deal, valued at approximately $9.
In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents
In a landmark development for computational medicine, Mass General Brigham (MGB) officially announced the launch of BrainIAC (Brain Imaging Adaptive Core) on February 5, 2026. This groundbreaking artificial intelligence foundation model represents a paradigm shift in how clinicians diagnose and treat neurological disorders. By utilizing a generalized architecture trained on tens of thousands of volumetric [...]
As of January 26, 2026, the medical community has officially entered the era of "Healthspan Engineering." A series of breakthroughs in artificial intelligence has transformed the humble chest X-ray—a diagnostic staple for over a century—into a sophisticated "biological clock." By utilizing deep learning models to analyze subtle anatomical markers invisible to the human eye, researchers [...]
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
The convergence of consumer technology and clinical medicine has reached a fever pitch as 2025 draws to a close. A landmark report released this December by ResearchAndMarkets.com projects that the wearable AI market will see a staggering $65 billion in incremental growth by 2030, driven almost entirely by its
November 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips’ leadership in precision neuro diagnostics, combining Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed.Combining complementary expertise for smarter brain imagingUp to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer’s disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system.Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images – enabling faster, more consistent, and confident diagnoses.Empowering clinicians with precision and speedThe integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS and brain tumors within Philips’ Smart Reading environment – a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] – marks a major step toward precision neuroimaging.With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence.“By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,” said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. “This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.”Driving productivity and improving care through AIPhilips is driving productivity and improving care through deep AI integration that tackles some of healthcare’s most pressing challenges – from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most – delivering a better, more personalized patient experience.“Cortechs.ai’s mission has always been to empower clinicians with actionable, quantitative insights,” said Kyle Frye, Chief Executive Officer, Cortechs.ai. “By combining our advanced neuro analytics with Philips’ leading MR platform and AI infrastructure, we’re making it easier to personalize brain care and track neurological changes with precision.”Setting a new standard in precision neuro diagnosticsCortechs.ai’s NeuroQuant® solutions are already available on Philips Advanced Visualization Workspace. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology – empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.
